

Caris Life Sciences (NASDAQ:CAI) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been...
You can purchase shares of Caris Life Sciences (NASDAQ:CAI) through any online brokerage.
Other companies in Caris Life Sciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Caris Life Sciences has a consensus price target of $30.54.
The stock price for Caris Life Sciences (NASDAQ: CAI) is $26.15 last updated November 5, 2026 at 9:42 AM EST.
There are no upcoming dividends for Caris Life Sciences.
Caris Life Sciences does not have any upcoming earnings scheduled.
There is no upcoming split for Caris Life Sciences.
Caris Life Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning...